PL2149372T3 - Zastosowanie opioidów z grupy metadonu w leczeniu opornych pacjentów onkologicznych - Google Patents
Zastosowanie opioidów z grupy metadonu w leczeniu opornych pacjentów onkologicznychInfo
- Publication number
- PL2149372T3 PL2149372T3 PL08013741T PL08013741T PL2149372T3 PL 2149372 T3 PL2149372 T3 PL 2149372T3 PL 08013741 T PL08013741 T PL 08013741T PL 08013741 T PL08013741 T PL 08013741T PL 2149372 T3 PL2149372 T3 PL 2149372T3
- Authority
- PL
- Poland
- Prior art keywords
- opioids
- treatment
- cancer patients
- resistant cancer
- methadone group
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08013741.7A EP2149372B1 (en) | 2008-07-31 | 2008-07-31 | Use of opioids of the methadone group for the treatment of resistant cancer patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2149372T3 true PL2149372T3 (pl) | 2015-03-31 |
Family
ID=40011012
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08013741T PL2149372T3 (pl) | 2008-07-31 | 2008-07-31 | Zastosowanie opioidów z grupy metadonu w leczeniu opornych pacjentów onkologicznych |
| PL09776348T PL2320900T3 (pl) | 2008-07-31 | 2009-01-29 | Opioidy do zastosowania w leczeniu opornych pacjentów onkologicznych |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09776348T PL2320900T3 (pl) | 2008-07-31 | 2009-01-29 | Opioidy do zastosowania w leczeniu opornych pacjentów onkologicznych |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8901175B2 (pl) |
| EP (2) | EP2149372B1 (pl) |
| JP (1) | JP5804945B2 (pl) |
| CN (1) | CN102159212B (pl) |
| BR (1) | BRPI0916555B1 (pl) |
| CA (1) | CA2732497C (pl) |
| DK (2) | DK2149372T3 (pl) |
| ES (2) | ES2482168T3 (pl) |
| HU (1) | HUE031337T2 (pl) |
| PL (2) | PL2149372T3 (pl) |
| PT (2) | PT2149372E (pl) |
| RU (1) | RU2520636C2 (pl) |
| WO (1) | WO2010012319A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011009020A2 (en) * | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
| PL2716291T3 (pl) | 2012-10-08 | 2020-06-15 | Universität Ulm | Połączenie opioidów i leków przeciwnowotworowych do leczenia nowotworów |
| AU2018351502B2 (en) * | 2017-10-20 | 2024-09-05 | Purdue Pharma L.P. | Pharmaceutical dosage forms |
| WO2019197015A1 (en) | 2018-04-09 | 2019-10-17 | Peter Truog | Composition comprising 4-phenylbutyric acid derivatives & opioids |
| CN110090303B (zh) * | 2019-05-07 | 2022-09-16 | 浙江大学 | 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途 |
| WO2020239948A1 (en) | 2019-05-28 | 2020-12-03 | Isanas Ag | A CENTRALLY ACTING µ-OPIOID RECEPTOR AGONIST IN COMBINATION WITH A CURCUMINOID FOR USE IN THE TREATMENT OF A TUMOUR OF THE CENTRAL NERVOUS SYSTEM |
| CN115844869B (zh) * | 2022-12-19 | 2024-08-16 | 新乡医学院 | 莱菔硫烷在逆转耐阿糖胞苷白血病细胞耐药性中的应用和药物组合物 |
| CN116173212A (zh) * | 2023-02-07 | 2023-05-30 | 杭州添帆生物科技有限公司 | 阿片类药物在制备黑色素瘤治疗药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173486A (en) * | 1991-08-26 | 1992-12-22 | Bristol-Myers Squibb Company | Dibenz[b,f][1,4]oxazepin-11(10H)-ones for multidrug resistance reversing agents |
| ES2440799T3 (es) * | 2005-05-13 | 2014-01-30 | Novartis Ag | Métodos para tratar cáncer resistente a los fármacos |
-
2008
- 2008-07-31 DK DK08013741.7T patent/DK2149372T3/da active
- 2008-07-31 PT PT80137417T patent/PT2149372E/pt unknown
- 2008-07-31 EP EP08013741.7A patent/EP2149372B1/en active Active
- 2008-07-31 ES ES08013741.7T patent/ES2482168T3/es active Active
- 2008-07-31 PL PL08013741T patent/PL2149372T3/pl unknown
-
2009
- 2009-01-29 PT PT97763486T patent/PT2320900T/pt unknown
- 2009-01-29 BR BRPI0916555-0A patent/BRPI0916555B1/pt active IP Right Grant
- 2009-01-29 DK DK09776348.6T patent/DK2320900T3/en active
- 2009-01-29 WO PCT/EP2009/000584 patent/WO2010012319A1/en active Application Filing
- 2009-01-29 EP EP09776348.6A patent/EP2320900B1/en active Active
- 2009-01-29 CN CN200980136278.9A patent/CN102159212B/zh active Active
- 2009-01-29 JP JP2011520333A patent/JP5804945B2/ja active Active
- 2009-01-29 CA CA2732497A patent/CA2732497C/en active Active
- 2009-01-29 US US13/056,918 patent/US8901175B2/en active Active
- 2009-01-29 HU HUE09776348A patent/HUE031337T2/hu unknown
- 2009-01-29 ES ES09776348.6T patent/ES2596363T3/es active Active
- 2009-01-29 PL PL09776348T patent/PL2320900T3/pl unknown
- 2009-01-29 RU RU2011107280/15A patent/RU2520636C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5804945B2 (ja) | 2015-11-04 |
| ES2482168T3 (es) | 2014-08-01 |
| RU2520636C2 (ru) | 2014-06-27 |
| DK2149372T3 (da) | 2014-07-07 |
| US8901175B2 (en) | 2014-12-02 |
| PT2149372E (pt) | 2014-07-25 |
| JP2011529454A (ja) | 2011-12-08 |
| EP2149372B1 (en) | 2014-04-02 |
| CA2732497A1 (en) | 2010-02-04 |
| WO2010012319A1 (en) | 2010-02-04 |
| CA2732497C (en) | 2017-01-17 |
| PT2320900T (pt) | 2016-10-13 |
| DK2320900T3 (en) | 2016-10-24 |
| ES2596363T3 (es) | 2017-01-09 |
| EP2320900A1 (en) | 2011-05-18 |
| BRPI0916555A2 (pt) | 2015-11-10 |
| HUE031337T2 (hu) | 2017-07-28 |
| US20110270011A1 (en) | 2011-11-03 |
| EP2149372A1 (en) | 2010-02-03 |
| CN102159212A (zh) | 2011-08-17 |
| EP2320900B1 (en) | 2016-07-06 |
| CN102159212B (zh) | 2015-09-16 |
| RU2011107280A (ru) | 2012-09-10 |
| BRPI0916555B1 (pt) | 2021-06-29 |
| PL2320900T3 (pl) | 2017-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL259475A (en) | Combined therapy for the treatment of diabetes | |
| IL248204A0 (en) | Combined treatment of tumors expressing 38cd | |
| ZA200906210B (en) | 3-Imidazolyl-Indoles for the treatment of proliferative diseases | |
| EP2332459A4 (en) | MEDICAL TREATMENT SYSTEM | |
| PT2303021T (pt) | Compostos para tratamento do cancro | |
| EP2049139A4 (en) | TREATMENT OF TUMORS EXPRESSING RAS | |
| PL2149372T3 (pl) | Zastosowanie opioidów z grupy metadonu w leczeniu opornych pacjentów onkologicznych | |
| HUE043235T2 (hu) | Terápiás kezelések tüdõbetegségekhez | |
| ZA201003425B (en) | 5-cyano-thienopyridines for the treatment of tumors | |
| GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
| PL2276498T3 (pl) | Zastosowanie bakterii probiotycznych do leczenia hiperhomocysteinemii | |
| EP2368499A4 (en) | TREATMENT INSTRUMENT | |
| GB0715790D0 (en) | Drug combination for the treatment of sialorrhoea | |
| IL210066A0 (en) | Novel ortho-aminoanilides for the treatment of cancer | |
| EP2361317A4 (en) | USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| ZA201001876B (en) | Treatment of lung cancer | |
| GB0700886D0 (en) | Medical treatment | |
| GB0915801D0 (en) | Theraputic treatment | |
| GB0720136D0 (en) | Treatment of blood disorded | |
| GB0600817D0 (en) | Medical treatment | |
| GB0817056D0 (en) | Polypeptide for treatment of cancer | |
| GB0920651D0 (en) | Molecular methods for the treatment of disease | |
| GB0809319D0 (en) | The treatment of puritus |